EP1292706A2 - Method of identifying ginko biloba in a plant extract by gene profiling - Google Patents
Method of identifying ginko biloba in a plant extract by gene profilingInfo
- Publication number
- EP1292706A2 EP1292706A2 EP01920817A EP01920817A EP1292706A2 EP 1292706 A2 EP1292706 A2 EP 1292706A2 EP 01920817 A EP01920817 A EP 01920817A EP 01920817 A EP01920817 A EP 01920817A EP 1292706 A2 EP1292706 A2 EP 1292706A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cdna
- treated
- untreated
- cells
- gene regulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 37
- 244000194101 Ginkgo biloba Species 0.000 title claims abstract description 29
- 239000000419 plant extract Substances 0.000 title description 2
- 230000033228 biological regulation Effects 0.000 claims abstract description 39
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims abstract description 37
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 34
- 229940068052 ginkgo biloba extract Drugs 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims abstract description 31
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 18
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 claims abstract description 12
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 claims abstract description 10
- 239000002299 complementary DNA Substances 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 51
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 claims description 9
- 102000049853 macrophage stimulating protein Human genes 0.000 claims description 9
- 108010053292 macrophage stimulating protein Proteins 0.000 claims description 9
- 102000015735 Beta-catenin Human genes 0.000 claims description 8
- 108060000903 Beta-catenin Proteins 0.000 claims description 8
- 101710109611 Cell division cycle protein 20 homolog Proteins 0.000 claims description 8
- 102000003780 Clusterin Human genes 0.000 claims description 8
- 108090000197 Clusterin Proteins 0.000 claims description 8
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 8
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 8
- 239000000893 inhibin Substances 0.000 claims description 8
- 108050006400 Cyclin Proteins 0.000 claims description 7
- 108700036622 ETS translocation variant 3 Proteins 0.000 claims description 7
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 claims description 7
- 108090000973 Myeloblastin Proteins 0.000 claims description 7
- 102100034681 Myeloblastin Human genes 0.000 claims description 7
- 102100037925 Prothymosin alpha Human genes 0.000 claims description 7
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 claims description 7
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 7
- 108010014750 prothymosin alpha Proteins 0.000 claims description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 6
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims description 6
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims description 6
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 claims description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
- 101001003233 Homo sapiens Immediate early response gene 2 protein Proteins 0.000 claims description 6
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims description 6
- 101000927793 Homo sapiens Neuroepithelial cell-transforming gene 1 protein Proteins 0.000 claims description 6
- 101001124937 Homo sapiens Pre-mRNA-splicing factor 38B Proteins 0.000 claims description 6
- 101000631937 Homo sapiens Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 claims description 6
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 claims description 6
- 102100020702 Immediate early response gene 2 protein Human genes 0.000 claims description 6
- 102000002746 Inhibins Human genes 0.000 claims description 6
- 108010004250 Inhibins Proteins 0.000 claims description 6
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 6
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 6
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 6
- 101150111584 RHOA gene Proteins 0.000 claims description 6
- 102100028886 Sodium- and chloride-dependent glycine transporter 2 Human genes 0.000 claims description 6
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 6
- 101150098203 grb2 gene Proteins 0.000 claims description 6
- KMXPHBJUGYLXDM-LSDHHAIUSA-N 1-[(7r,8s)-7-hydroxy-6,6-dimethyl-7,8-dihydropyrano[2,3-f][2,1,3]benzoxadiazol-8-yl]piperidin-2-one Chemical compound N1([C@H]2C3=CC4=NON=C4C=C3OC([C@@H]2O)(C)C)CCCCC1=O KMXPHBJUGYLXDM-LSDHHAIUSA-N 0.000 claims description 5
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 5
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 5
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 5
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 5
- 102000005720 Glutathione transferase Human genes 0.000 claims description 5
- 108010070675 Glutathione transferase Proteins 0.000 claims description 5
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 5
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 claims description 5
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 5
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 5
- 101100225582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nip-1 gene Proteins 0.000 claims description 5
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 claims description 5
- 102100026445 A-kinase anchor protein 17A Human genes 0.000 claims description 4
- -1 ETR-103 Proteins 0.000 claims description 4
- 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 claims description 4
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims description 4
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 4
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 4
- 101001015059 Homo sapiens Integrin beta-5 Proteins 0.000 claims description 4
- 102100032819 Integrin alpha-3 Human genes 0.000 claims description 4
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 4
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 4
- 102100033010 Integrin beta-5 Human genes 0.000 claims description 4
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims description 4
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 claims description 3
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 108700024542 myc Genes Proteins 0.000 claims description 3
- 238000012795 verification Methods 0.000 claims description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 3
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 2
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 claims 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
- 102100039562 ETS translocation variant 3 Human genes 0.000 claims 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 abstract description 2
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 abstract description 2
- 108020004635 Complementary DNA Proteins 0.000 description 34
- 238000010804 cDNA synthesis Methods 0.000 description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 230000004663 cell proliferation Effects 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 9
- 229930184727 ginkgolide Natural products 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 150000003505 terpenes Chemical class 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 102100022407 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase Human genes 0.000 description 5
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 101800001622 120 kDa surface-exposed protein Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 4
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 108010016283 TCF Transcription Factors Proteins 0.000 description 2
- 102000000479 TCF Transcription Factors Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108010048673 Vitronectin Receptors Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 101150073031 cdk2 gene Proteins 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001573 trophoblastic effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- 102000015936 AP-1 transcription factor Human genes 0.000 description 1
- 108050004195 AP-1 transcription factor Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108700020472 CDC20 Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101150023302 Cdc20 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 101000979223 Homo sapiens N-terminal EF-hand calcium-binding protein 3 Proteins 0.000 description 1
- 101000589482 Homo sapiens Nuclear cap-binding protein subunit 2 Proteins 0.000 description 1
- 101000973947 Homo sapiens Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase Proteins 0.000 description 1
- 101000873111 Homo sapiens Vesicle transport protein SEC20 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101000973942 Mus musculus Probable 28S rRNA (cytosine-C(5))-methyltransferase Proteins 0.000 description 1
- 102100023213 N-terminal EF-hand calcium-binding protein 3 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010049404 Prokaryotic Initiation Factor-3 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 108010078931 elastase receptor Proteins 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 108091008800 n-Myc Proteins 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical class CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 230000001792 virilizing effect Effects 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Definitions
- the present invention is directed to a method of establishing an "identity" of Ginkgo biloba leaves or isolated ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves, by obtaining a "gene regulation profile".
- the invention is also directed to a method of verifying the identity of a Ginkgo biloba extract by comparing the gene regulation profile of a Gingko biloba extract of unknown or questionable origin with the gene regulation profile of a Gingko biloba extract of known origin.
- known origin refers to the commercial source of the extract.
- a preferred aspect of the present invention is where the Ginkgo biloba extract of known origin is EGB 761®, produced and marketed by IPSEN of Paris, France.
- this invention is directed to a method for determining the authenticity of an extract of unknown origin purporting to be EGB 761®.
- the present invention is further directed to a method of establishing a gene expression profile of Ginkgolide A, Ginkgolide B or any other component isolated from a Ginkgo biloba extract, more particularly, from EGB 761®.
- composition is based on control over the composition and the consistency of the biological activity profile of a manufactured batch. This standardization and control provides reproducible material in the predictable and consistent treatment of patients. Such use of standardization and control to guard against the marketing of counterfeit extracts purporting to be EGB 761® is beneficial to patients since it assures patients that they are obtaining/receiving an extract with a particular biological activity profile.
- Ginkgo biloba is one of the most ancient trees, and extracts from its leaves have been used in traditional medicine for several hundred years. There are numerous studies describing the beneficial effects of Ginkgo biloba extracts on patients with disturbances in vigilance, memory, and cognitive functions associated with aging and senility, and on those with all types of dementias, mood changes, and the ability to cope with daily stressors.
- a standardized extract of Ginkgo biloba leaves, termed EGB 761® has been used in most of these studies. This extract is also known to have cardioprotective effects (DeFeudis F.V. Ginkgo biloba extract (EGB 761®): from chemistry to clinic. Ullstein Medical, Wisbaden, Germany. 400 pp.
- EGB 761® Ginkgo biloba Extract
- the extract contains 24% ginkgo-flavone glycosides, 6% terpene lactones (ginkgolides and bilobalide), about 7% proanthocyanidins and several other constituents. See Boralle, N., et al., In: Ginkgolides, Chemistry, Biology, Pharmacology and Clinical perspectives, Ed: Braquet, P., J.R. Prous Science Publishers, 1988.
- the present invention is directed to a method of establishing a gene regulation profile of a Gingko biloba extract or a component of the Ginkgo biloba extract, which comprises the steps of: obtaining at least one batch of untreated cells; treating a first batch of cells with an extract of Ginkgo biloba or a component of the Ginkgo biloba extract to obtain a treated batch of cells; quantifying an affect on the expression of one or more genes of the treated cells to obtain a quantity of affected genes; and comparing the quantity of affected genes with a quantity of genes of cells not treated with Ginkgo biloba or a component of the Ginkgo biloba extract to obtain the gene regulation profile of the Ginkgo biloba extract or a component of the Ginkgo biloba extract.
- a preferred method of the foregoing method is where the quantifying step comprises: isolating poly A+ RNA from the treated batch of cells to obtain treated poly A+ RNA; isolating poly A+ RNA from a batch of untreated cells to obtain untreated poly A+ RNA; generating labeled cDNA probes from the treated poly A+ RNA to obtain treated labeled cDNA probes; generating labeled cDNA probes from the untreated poly A+ RNA to obtain untreated labeled cDNA probes; hybridizing the treated cDNA probes to an array having one or more cDNA to obtain a treated hybridized array of cDNA; hybridizing the untreated cDNA probes to an array having one or more cDNA to obtain an untreated hybridized array of cDNA; quantifying each of the cDNA of the treated hybridized array of cDNA to obtain quantities of treated cDNA; quantifying each of the cDNA of the untreated hybridized array of cDNA to obtain quantities of untreated cDNA; and comparing
- MDA-231 cells the Ginkgo biloba extract is EGB 761®; and the array is a gene chip having multiple genes.
- a preferred method of the immediately foregoing method is where the gene regulation profile of EGB 761® comprises increased expression of c-Myc protooncogene, and decreased expression of the following genes: prothymosin- ⁇ ,
- CDK2 CDK2, p55CDC, myeloblastin p120 proliferating-cell nuclear antigen, NET1, ERK2,
- CDK2 -83%
- TRADD -51%
- B-lymphocyte Antigen -62%
- L1CAM -72%
- ⁇ -catenin -58%
- Integrin Subunit ⁇ M -41%
- Integrin Subunit ⁇ 5 -55%
- CSF-1 Macrophage Colony-stimulating Factor-1
- Heparin-binding EGF-like Growth Factor (HB-EGF) -62%
- HGFLP Hepatocyte Growth Factor-like Protein
- the present invention provides a method of verifying the identity of a Ginkgo biloba extract which comprises the steps of: obtaining a gene regulation profile of the Gingko biloba extract to obtain a gene regulation profile; obtaining a gene regulation profile of EGB 761® to yield an EGB 761® gene regulation profile; comparing the gene regulation profile of the Gingko biloba extract with the EGB
- a preferred method of the immediately foregoing method is where the method of obtaining a gene regulation profile of the Ginkgo biloba extract and the EGB 761® gene regulation profile comprises the steps of: isolating poly A+ RNA from the treated batch of cells to obtain treated poly A+ RNA; isolating poly A+ RNA from a batch of untreated cells to obtain untreated poly A+ RNA; generating labeled cDNA probes from the treated poly A+ RNA to obtain treated labeled cDNA probes; generating labeled cDNA probes from the untreated poly A+ RNA to obtain untreated labeled cDNA probes; hybridizing the treated cDNA probes to an array having one or more cDNA to obtain a treated hybridized array of cDNA; hybridizing the untreated cDNA probes to an array having one or more cDNA to obtain an untreated hybridized array of cDNA; quantifying each of the cDNA of the treated hybridized array of cDNA to obtain quantities of treated cDNA; quantifying each
- ginkgo terpenoid includes all of the naturally occurring terpenes which are derived from the gymnosperms tree Ginkgo biloba as well as synthetically produced ginkgo terpenoids and pharmaceutically active derivatives and salts thereof and mixtures thereof.
- examples of ginkgo terpenoids include ginkgolides.
- Examples of ginkgo terpenoids are disclosed in Ginkgolides, Chemistry, Biology, Pharmacology, and Clinical Perspectives, J.R. Provs. Science Publishers, Edited by P. Braguet (1988); F.V. DeFeudis, Ginkgo Biloba Extract (EGB 761®); Pharmacological Activities and Clinical Applications, Elsevier, Chapter II (1991).
- ginkgolide as used herein include the various ginkgolides disclosed in the books cited above as well as non-toxic pharmaceutically active derivatives thereof.
- examples of ginkgolide derivatives include tetrahydro derivatives, acetyl derivatives, and alkyl esters such as the monoacetate derivatives and triacetate derivatives disclosed in Okabe, et al., J. Chem. Soc. (c), pp. 2201-2206 (1967).
- Ginkgolide B has the following structure and as used herein, refers to isolated ginkgolide B:
- Ginkgo biloba extract includes a collection of natural molecules, including terpenoids, derived from the leaves of the Ginkgo biloba tree.
- the extract is the specific formulation of Ginkgo biloba extract known as EGB 761®.
- a gene expression profile of an extract of Ginkgo biloba or a component thereof can be obtained by methods known in the art. Traditionally such a profile was obtained by RNA Northern blot analysis or ribonuclease protection assay for each individual gene product. However, these assays were time consuming and took about 2-3 days to analyze each gene. Currently a gene expression profile can be established through the utilization of nucleic acid array technology such as the Atlas human cDNA expression array I from Clontech (Palo Alto, CA); GeneFilters Microarrays by Research Genetics (Huntsville, AL); and the Gene Expression Microarrays by Genome Systems, Inc. (St. Louis, MO).
- nucleic acid array technology such as the Atlas human cDNA expression array I from Clontech (Palo Alto, CA); GeneFilters Microarrays by Research Genetics (Huntsville, AL); and the Gene Expression Microarrays by Genome Systems, Inc. (St. Louis, MO).
- the Gene Filters Microarray are high density DNA arrays produced on 5 cm x 7 cm membranes. At present there are four membranes available for human genes and one for rat genes. Each membrane contains approximately 5,000 sequences. Some of these sequences are known genes, while most sequences represent ESTs of unknown function. Research Genetics will soon make available gene arrays on the Affymetrix Gene chip platform, where the genes are immobilized on a silicon chip. In the case of silicon chips, the hybridization results (with the mRNA of choice) are detected by fluorescence and analyzed by pattern recognition compared to either fluorescence or radioactivity that can be used for the detection of the hybridization results in the membrane arrays.
- Genome System's method utilizes the GEM technology where a collection of complementary DNA (cDNA) molecules that contain the genetic information from the biological systems of interest are deposited and bonded on a glass surface in an array format. Next, large portions from one half of the DNA's double strand are removed, thus activating the individual elements of the array, preparing them to react with their uniquely matched DNA counterparts in the cells being tested.
- GEM technology can fit 10,000 unique genes on a single array. GEM technology also uses a color coded technique to examine the difference in expression between two mRNA samples.
- An array of cDNA will contain numerous animal, such as rat or human, preferably human, PCR-amplified cDNA fragments immobilized on a positively charged nylon membrane or a glass slide or a silicon chip or any other surface to be developed where a DNA/matrix interaction is allowed.
- a cell type of interest is treated with and without a Ginkgo biloba extract or a component thereof for about 48 hours.
- Poly A+ RNA is isolated from control and extract-treated cells.
- 32 P-labeled, fluorescent, chemiluminescent or colorimetric cDNA probes, preferably fluorescent or colorimetric labeling when using glass or silicon chip arrays, are generated from each poly A+RNA and hybridized to the array according to the manufacturer's recommendations.
- Autoradiography is performed by exposing the blots to film at about -70°C for 4-96 hr. Quantification of the hybridization is carried out using an imaging system, which can detect the fluorescence or chemiluminesence then capture the image and analyze the data, such as the SigmaGel software. Multiple exposures are used in order to detect genes expressed at low levels.
- the three internal controls, ubiquitin, G3PDH and ⁇ - actin are used to compare the relative expression levels of the detected gene products in the control and the extract-treated cells. Experimental variations are corrected using the ratios of gene expression versus the internal controls. The effect of the extract treatment on each gene product is expressed as % of control (untreated) cells.
- the Atlas human cDNA expression array I from Clontech contains 588 human PCR-amplified cDNA fragments of 200-500 bp long immobilized on a positively charged nylon membrane.
- MDA-231 cells were treated with and without 20 ⁇ g/ml EGB 761® for 48 hours.
- Poly A+ RNA was isolated from control and EGB 761 ⁇ -treated cells.
- 32 P-labeled cDNA probes were generated from each poly A+RNA and hybridized to the Atlas array according to the manufacturer's recommendations.
- Table I shows genes affected consistently, at a level above 30% of control, by the EGB 761® treatment.
- Table I shows that the treatment increased the expression of the c-Myc protooncogene and decreased the expression of 35 gene products, including oncogenes (AP-1, PE-1, RhoA, n-Myc), cell cycle regulators (CDK2, p55CDC, PCNA p120), signal transduction modulators (NET1, ERK2), apoptosis- related products (SGP-2, NIP1) receptors (A2A, RXR-beta, Grb2), transcription factors (ld-2, ATF-4, ETR101, ETR-103), growth factors (HB-EGF, HGF-like), and cell adhesion molecules (CD19, L1CAM, integrins ⁇ 3, ⁇ 4, ⁇ 6, ⁇ 5, Mac-1, ⁇ -catenin) which are directly involved in various pathways regulating cell proliferation.
- oncogenes AP-1, PE-1, RhoA, n-
- Gene expression profiles can be established for Ginkgo biloba extracts of known origin and then can be compared with the gene expression profile of Ginkgo biloba extracts of unknown origin or extracts that purport to be a certain commercial extract. The comparison of the profiles can thus be used as a screening means to authenticate the origin of an extract.
- CDK2 -83% -cyclin-dependent tyrosine kinase involved in progression through the (49) cell cycle
- ERK2 -46% -member of the extracellular signal-related protein kinase family (52)
- Antigen -expression is down-regulated during retinoid-inhibition of lymphoblastoid B-cell proliferation
- L1 CAM expression is associated with high-grade migration of glioma cells ⁇ -catenin -58% -involved in cadherin-mediated cell-cell interactions (74)
- Macrophage Colony- -31% -regulates the proliferation, differentiation, and survival of monocytes, (83) stimulating Factor-1 macrophages and their precursors (84)
- CSF-1 -initiates a mitogenic signal that is required throughout G1 phase -CSF-1 stably transfected ovarian granulosa cells exhibit enhanced cell proliferation
- HB-EGF Growth Factor
- HGFLP human keratinocytes lnhibin ⁇ -69% -a member of the inhibin family of heterodimeric growth factors (88) -inhibin ⁇ is a marker of trophoblastic neoplasia and is highly (89) expressed in virilizing adenomas
- FADD/MORT1 A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes.
- Atf4 suppresses c-Ha-ras oncogene transcript levels and cellular transformation in
- prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34(cdc2). Cancer, 85: 1569-1576, 1999.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is directed to a method of establishing an 'identity' of Ginkgo biloba leaves or isolated ginkgolide B (GKB) or another component of the extract of Ginkgo biloba leaves, by obtaining a 'gene regulation profile'. The invention is also directed to a method of verifying the identity of a Ginkgo biloba extract by comparing the gene regulation profile of a Gingko biloba extract of unknown or questionable origin with the gene regulation pofile of a Gingko biloba extract of known origin. The present invention is further directed to a method of establishing a gene expression profile of Ginkgolide A, Ginkgolide B or any other component isolated from a Ginkgo biloba extract, more particularly, from EGB 761®.
Description
METHOD OF PROFILING A PLANT EXTRACT Statement Regarding Federally Sponsored Research
The present invention was sponsored in part by grants ES-07747 NIEHS, from the National Institutes of Health and, thus, the U.S. government may have certain rights in the present invention.
Background of the Invention The present invention is directed to a method of establishing an "identity" of Ginkgo biloba leaves or isolated ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves, by obtaining a "gene regulation profile". The invention is also directed to a method of verifying the identity of a Ginkgo biloba extract by comparing the gene regulation profile of a Gingko biloba extract of unknown or questionable origin with the gene regulation profile of a Gingko biloba extract of known origin. The term "known origin" refers to the commercial source of the extract. A preferred aspect of the present invention is where the Ginkgo biloba extract of known origin is EGB 761®, produced and marketed by IPSEN of Paris, France. More particularly, this invention is directed to a method for determining the authenticity of an extract of unknown origin purporting to be EGB 761®. The present invention is further directed to a method of establishing a gene expression profile of Ginkgolide A, Ginkgolide B or any other component isolated from a Ginkgo biloba extract, more particularly, from EGB 761®.
Pharmaceutical manufacturing is based on control over the composition and the consistency of the biological activity profile of a manufactured batch. This standardization and control provides reproducible material in the predictable and consistent treatment of patients. Such use of standardization and control to guard against the marketing of counterfeit extracts purporting to be EGB 761® is beneficial to patients since it assures patients that they are obtaining/receiving an extract with a particular biological activity profile.
Ginkgo biloba is one of the most ancient trees, and extracts from its leaves have been used in traditional medicine for several hundred years. There are numerous studies describing the beneficial effects of Ginkgo biloba extracts on patients with disturbances in vigilance, memory, and cognitive functions associated with aging and senility, and on those with all types of dementias, mood changes, and the ability to cope with daily stressors. A standardized extract of Ginkgo biloba leaves, termed EGB
761®, has been used in most of these studies. This extract is also known to have cardioprotective effects (DeFeudis F.V. Ginkgo biloba extract (EGB 761®): from chemistry to clinic. Ullstein Medical, Wisbaden, Germany. 400 pp. 1998; Tosaki, A., Droy-Lefaix, M.T., Pali, T., and Das, D.K., Free Rad. Biol. Med., 14: 361-370, 1993). These effects have been attributed, at least in part, to the free radical scavenging properties of EGB 761®, probably due to the presence of flavonoid or terpenoid constituents in the extract. Recent in vivo and in vitro studies demonstrated that the terpene constituents of EGB 761®, ginkgolides and bilobalide, have anti-oxidant properties (Pietri, S., Maurelli, E., Drieu, K., and Culcasi, M., J. Mol. Cell. Cardiol., 29: 733-742, 1997; Yao, Z., Boujrad, N., Drieu, K., and Papadopoulos, V., Adv. Ginkgo Biloba Res. 7: 129-138, 1998). Other studies of EGB 761® have reported medicinal value of the product in the treatment of a variety of clinical disorders including cerebrovascular and peripheral vascular insufficiencies associated with aging and senility. See e.g., Ginkgo biloba Extract (EGB 761®) Pharmacological Activities and Clinical Applications, DeFeudis, F.V., Eds, Elsevier, 1991; and Ullstein Medical 1998, Ginkgo biloba extract (EGB 761®), Eds. Wiesbaden, DeFeudis, F.V. The extract contains 24% ginkgo-flavone glycosides, 6% terpene lactones (ginkgolides and bilobalide), about 7% proanthocyanidins and several other constituents. See Boralle, N., et al., In: Ginkgolides, Chemistry, Biology, Pharmacology and Clinical perspectives, Ed: Braquet, P., J.R. Prous Science Publishers, 1988.
More frequently, counterfeit formulations purporting to be EGB 761® are being placed in the stream of commerce. Such counterfeits do not possess the same composition of components that constitute authentic EGB 761®. Patients who obtain counterfeit EGB 761®, believing that the counterfeit is authentic, are being deprived the benefit of EGB 761 ®'s full range of biological activity. Further, the good will associated with EGB 761® is being eroded. Hence, there is a need for a method of establishing the biological activity profile of EGB 761®, which can then be used to compare with the biological activity profile of a counterfeit EGB 761 to screen such counterfeits from the marketplace.
Summary of the Invention
The present invention is directed to a method of establishing a gene regulation profile of a Gingko biloba extract or a component of the Ginkgo biloba extract, which comprises the steps of: obtaining at least one batch of untreated cells; treating a first batch of cells with an extract of Ginkgo biloba or a component of the Ginkgo biloba extract to obtain a treated batch of cells; quantifying an affect on the expression of one or more genes of the treated cells to obtain a quantity of affected genes; and comparing the quantity of affected genes with a quantity of genes of cells not treated with Ginkgo biloba or a component of the Ginkgo biloba extract to obtain the gene regulation profile of the Ginkgo biloba extract or a component of the Ginkgo biloba extract.
A preferred method of the foregoing method is where the quantifying step comprises: isolating poly A+ RNA from the treated batch of cells to obtain treated poly A+ RNA; isolating poly A+ RNA from a batch of untreated cells to obtain untreated poly A+ RNA; generating labeled cDNA probes from the treated poly A+ RNA to obtain treated labeled cDNA probes; generating labeled cDNA probes from the untreated poly A+ RNA to obtain untreated labeled cDNA probes; hybridizing the treated cDNA probes to an array having one or more cDNA to obtain a treated hybridized array of cDNA; hybridizing the untreated cDNA probes to an array having one or more cDNA to obtain an untreated hybridized array of cDNA; quantifying each of the cDNA of the treated hybridized array of cDNA to obtain quantities of treated cDNA; quantifying each of the cDNA of the untreated hybridized array of cDNA to obtain quantities of untreated cDNA; and comparing the quantities of each of the treated cDNA with the quantities of untreated cDNA to obtain the gene regulation profile.
A preferred method of the immediately foregoing method is where the cells are
MDA-231 cells; the Ginkgo biloba extract is EGB 761®; and the array is a gene chip having multiple genes.
A preferred method of the immediately foregoing method is where the gene regulation profile of EGB 761® comprises increased expression of c-Myc protooncogene, and decreased expression of the following genes: prothymosin-α,
CDK2, p55CDC, myeloblastin p120 proliferating-cell nuclear antigen, NET1, ERK2,
Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR-β, Glutathione S- transferase P, N-Myc, TRADD, SGP-2, NIP-1, ld-2, ATF-4, ETR101, ETR-103, macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein, inhibin α, CD19 B-lymphocyte antigen, L1CAM, β- catenin, integrin subunit α3, integrin subunit α4, integrin subunit α6, integrin subunit β5, integrin subunit αM, APC, PE-1, RhoA, c-Jun, prothymosin-α, CDK2, p55CDC and myeloblastin. A preferred method of the immediately foregoing method is where the gene regulation profile of EGB 761® is about c-Myc = +75%, c-Jun = -78%,
RhoA = -93%, APC = -59%,
PE-1 = -42%,
Prothymosin-α = -79%,
Myeloblastin = -66%, p55CDC = -63%, p120 Proliferating-cell Nuclear Antigen = -68%,
CDK2 = -83%,
NET1 = -55%,
ERK2 = -46%,
Adenosine A2A Receptor = -40%, Flt3 ligand = -58%,
Grb2 = -70%,
Clusterin = -54%,
RXR-β = -55%,
Glutathione S-transf erase P = -39%,
N-Myc = -74%,
TRADD = -51%,
NIP-1 = -40%, ld-2 = -65%,
ATF4 = -42%,
ETR103 = -65%,
ETR101 = -60%,
CD19 B-lymphocyte Antigen = -62%, L1CAM = -72%, β-catenin = -58%,
Integrin Subunit αM = -41%,
Integrin Subunit β5 = -55%,
Integrin Subunit α4 = -49%, Integrin Subunit α3 = -77%,
Integrin Subunit α6 = -53%,
Macrophage Colony-stimulating Factor-1 (CSF-1) = -31%,
Heparin-binding EGF-like Growth Factor (HB-EGF) = -62%,
Hepatocyte Growth Factor-like Protein (HGFLP) = -81%, and Inhibin α = -69%, wherein the percentages shown can be ±20%.
A preferred method of any of the foregoing methods is where the cells are MDA- 231 cells; the component of the Ginkgo biloba extract is Ginkgolide B; and the array is a gene chip having multiple genes. In another aspect, the present invention provides a method of verifying the identity of a Ginkgo biloba extract which comprises the steps of: obtaining a gene regulation profile of the Gingko biloba extract to obtain a gene regulation profile; obtaining a gene regulation profile of EGB 761® to yield an EGB 761® gene regulation profile; comparing the gene regulation profile of the Gingko biloba extract with the EGB
761® gene regulation profile;
determining whether the values of the gene regulation profile of the Ginkgo biloba extract is within ±10% of the values of the EGB 761® gene regulation profile to obtain verification of the identity of the Ginkgo biloba extract.
A preferred method of the immediately foregoing method is where the method of obtaining a gene regulation profile of the Ginkgo biloba extract and the EGB 761® gene regulation profile comprises the steps of: isolating poly A+ RNA from the treated batch of cells to obtain treated poly A+ RNA; isolating poly A+ RNA from a batch of untreated cells to obtain untreated poly A+ RNA; generating labeled cDNA probes from the treated poly A+ RNA to obtain treated labeled cDNA probes; generating labeled cDNA probes from the untreated poly A+ RNA to obtain untreated labeled cDNA probes; hybridizing the treated cDNA probes to an array having one or more cDNA to obtain a treated hybridized array of cDNA; hybridizing the untreated cDNA probes to an array having one or more cDNA to obtain an untreated hybridized array of cDNA; quantifying each of the cDNA of the treated hybridized array of cDNA to obtain quantities of treated cDNA; quantifying each of the cDNA of the untreated hybridized array of cDNA to obtain quantities of untreated cDNA; and comparing the quantities of each of the treated cDNA with the quantities of untreated cDNA to obtain the gene regulation profile.
Brief Description of the Drawings Figure 1. Transcriptional response to EGB 761® suggests an effect on genes involved in cell proliferation. Results shown represent quantitative analysis of the Atlas human cDNA expression array containing 588 PCR-amplified cDNA fragments (Clontech Inc.). RNAs were obtained from control or EGB 761 ® (20 μg/ml) treated, for 48 h, MDA-231 cells. For normalizing the mRNA abundance, the densitometric values obtained from image analysis were normalized using the housekeeping genes provided in the array. Only consistent significant changes above 30% were considered.
Detailed Description
The term "ginkgo terpenoid" includes all of the naturally occurring terpenes which are derived from the gymnosperms tree Ginkgo biloba as well as synthetically produced ginkgo terpenoids and pharmaceutically active derivatives and salts thereof and mixtures thereof. Examples of ginkgo terpenoids include ginkgolides. Examples of ginkgo terpenoids are disclosed in Ginkgolides, Chemistry, Biology, Pharmacology, and Clinical Perspectives, J.R. Provs. Science Publishers, Edited by P. Braguet (1988); F.V. DeFeudis, Ginkgo Biloba Extract (EGB 761®); Pharmacological Activities and Clinical Applications, Elsevier, Chapter II (1991). The term "ginkgolide" as used herein include the various ginkgolides disclosed in the books cited above as well as non-toxic pharmaceutically active derivatives thereof. Examples of ginkgolide derivatives include tetrahydro derivatives, acetyl derivatives, and alkyl esters such as the monoacetate derivatives and triacetate derivatives disclosed in Okabe, et al., J. Chem. Soc. (c), pp. 2201-2206 (1967). Ginkgolide B has the following structure and as used herein, refers to isolated ginkgolide B:
The term "Ginkgo biloba extract" as used herein includes a collection of natural molecules, including terpenoids, derived from the leaves of the Ginkgo biloba tree. Preferably, the extract is the specific formulation of Ginkgo biloba extract known as EGB 761®.
A gene expression profile of an extract of Ginkgo biloba or a component thereof can be obtained by methods known in the art. Traditionally such a profile was obtained by RNA Northern blot analysis or ribonuclease protection assay for each individual gene product. However, these assays were time consuming and took about 2-3 days to analyze each gene. Currently a gene expression profile can be established through the utilization of nucleic acid array technology such as the Atlas human cDNA expression
array I from Clontech (Palo Alto, CA); GeneFilters Microarrays by Research Genetics (Huntsville, AL); and the Gene Expression Microarrays by Genome Systems, Inc. (St. Louis, MO). The Gene Filters Microarray are high density DNA arrays produced on 5 cm x 7 cm membranes. At present there are four membranes available for human genes and one for rat genes. Each membrane contains approximately 5,000 sequences. Some of these sequences are known genes, while most sequences represent ESTs of unknown function. Research Genetics will soon make available gene arrays on the Affymetrix Gene chip platform, where the genes are immobilized on a silicon chip. In the case of silicon chips, the hybridization results (with the mRNA of choice) are detected by fluorescence and analyzed by pattern recognition compared to either fluorescence or radioactivity that can be used for the detection of the hybridization results in the membrane arrays.
Genome System's method utilizes the GEM technology where a collection of complementary DNA (cDNA) molecules that contain the genetic information from the biological systems of interest are deposited and bonded on a glass surface in an array format. Next, large portions from one half of the DNA's double strand are removed, thus activating the individual elements of the array, preparing them to react with their uniquely matched DNA counterparts in the cells being tested. GEM technology can fit 10,000 unique genes on a single array. GEM technology also uses a color coded technique to examine the difference in expression between two mRNA samples.
An array of cDNA will contain numerous animal, such as rat or human, preferably human, PCR-amplified cDNA fragments immobilized on a positively charged nylon membrane or a glass slide or a silicon chip or any other surface to be developed where a DNA/matrix interaction is allowed. A cell type of interest is treated with and without a Ginkgo biloba extract or a component thereof for about 48 hours. Poly A+ RNA is isolated from control and extract-treated cells. 32P-labeled, fluorescent, chemiluminescent or colorimetric cDNA probes, preferably fluorescent or colorimetric labeling when using glass or silicon chip arrays, are generated from each poly A+RNA and hybridized to the array according to the manufacturer's recommendations. Autoradiography is performed by exposing the blots to film at about -70°C for 4-96 hr. Quantification of the hybridization is carried out using an imaging system, which can detect the fluorescence or chemiluminesence then capture the image and analyze the data, such as the SigmaGel software. Multiple exposures are used in order to detect
genes expressed at low levels. The three internal controls, ubiquitin, G3PDH and β- actin are used to compare the relative expression levels of the detected gene products in the control and the extract-treated cells. Experimental variations are corrected using the ratios of gene expression versus the internal controls. The effect of the extract treatment on each gene product is expressed as % of control (untreated) cells.
An example of the foregoing type of gene expression profile is as follows. The Atlas human cDNA expression array I from Clontech (Palo Alto.CA) contains 588 human PCR-amplified cDNA fragments of 200-500 bp long immobilized on a positively charged nylon membrane. MDA-231 cells were treated with and without 20 μg/ml EGB 761® for 48 hours. Poly A+ RNA was isolated from control and EGB 761 ©-treated cells. 32P-labeled cDNA probes were generated from each poly A+RNA and hybridized to the Atlas array according to the manufacturer's recommendations. Autoradiography was performed by exposing the blots to X-OMAT AR film (Kodak, Rochester, NY) at - 70°C for 4-96 hr. Quantification of the hybridization seen was carried out using the SigmaGel software (Jandel Scientific, San Rafael, CA). Multiple exposures were used in order to detect genes expressed at low levels. The three internal controls, ubiquitin, G3PDH and β-actin were used to compare the relative expression levels of the detected gene products in the control and EGB 761 ©-treated cells. Experimental variations were corrected using the ratios of gene expression versus the internal controls. The effect of the EGB 761® treatment on each gene product is expressed as % of control (untreated) cells. The results of this experiment, which is presented in Table I, show genes affected consistently, at a level above 30% of control, by the EGB 761® treatment. In summary, Table I shows that the treatment increased the expression of the c-Myc protooncogene and decreased the expression of 35 gene products, including oncogenes (AP-1, PE-1, RhoA, n-Myc), cell cycle regulators (CDK2, p55CDC, PCNA p120), signal transduction modulators (NET1, ERK2), apoptosis- related products (SGP-2, NIP1) receptors (A2A, RXR-beta, Grb2), transcription factors (ld-2, ATF-4, ETR101, ETR-103), growth factors (HB-EGF, HGF-like), and cell adhesion molecules (CD19, L1CAM, integrins α3, α4, α6, β5, Mac-1, β-catenin) which are directly involved in various pathways regulating cell proliferation.
Gene expression profiles can be established for Ginkgo biloba extracts of known origin and then can be compared with the gene expression profile of Ginkgo biloba extracts of unknown origin or extracts that purport to be a certain commercial
extract. The comparison of the profiles can thus be used as a screening means to authenticate the origin of an extract.
Table I: Effect of EGB 761® on MDA-231 gene expression examined using the Atlas human cDNA expression array as described under Nucleic Acid Arrays.
Name % Change Function References
Oncogenes and Tumor Suppressers c-Myc +75% -basic helix-loop-helix-leucine zipper transcription factor (37) -Myc/Max heterodimers induce cell-cycle progression, apoptosis, and malignant transformation c-Jun -78% -part of the AP-1 transcription factor that regulates genes involved in (38) cell proliferation RhoA -93% -GTP-binding protein that is an important regulator of cell proliferation (39)
-RhoA inactivation inhibits HL60 cell proliferation (40) APC -59% -APC mutations are associated with both hereditary and sporadic (41 ) colorectal cancers (42) -a negative post-translational regulator of β-catenin
PE-1 -42% -transcription factor (43) Cell Cycle Control Proteins
Prothymosin-α -79% -acidic nuclear protein that is upregulated in proliferating thymocytes, (44) lymphocytes from leukemia patients, and in malignant breast lesions
Myeloblastin -66% -a serine protease involved in leukemia cell differentiation (45) p55CDC -63% -similar to mitosis regulators CDC4 and CDC20 (46)
-expression positively correlated with cell proliferation status p120 Proliferating-cell -68% -nucleolar protein expressed in proliferating cells (47) Nuclear Antigen -a prognostic indicator for breast cancer patients and prostate (48) adenocarcinoma
CDK2 -83% -cyclin-dependent tyrosine kinase involved in progression through the (49) cell cycle
-cyclin E/Cdk2 inactivates the retinoblastoma tumor suppresser to allow the cell to progress to S phase (50)
-Vitamin D inhibition of LNCaP cell proliferation coincided with a reduction in Cdk2 activity
Intr acellular Transducers
NET1 -55% -RhoA-specific guanine exchange factor (51 )
-NIH3T3-transforming protein
ERK2 -46% -member of the extracellular signal-related protein kinase family (52)
-activated upon cell stimulation
Apoptosis-Related Proteins
Adenosine A2A Receptor -40% -G protein-coupled receptor involved in the cAMP signaling pathway (53) Flt3 ligand -58% -ligand for the Flt3 cytokine receptor tyrosine kinase (54)
-induces proliferation of leukemic myeloid cells
Grb2 -70% -an adapter protein that links receptor tyrosine kinases to the (55)
Ras/MAPK signaling pathway via its SH2 domain
Clusterin -54% -a glycoprotein associated with cell adhesion and apoptosis (56, 57)
-increased expression is linked to Alzheimer's disease (58)
RXR-β -55% -retiniod-activated transcription factor (59)
-inhibition of chondrocyte proliferation by retinoic acid causes a (60) reduction in RXR-β mRNA expression
Glutathione S-transferase -39% -a multi-drug resistance gene that is overexpressed in various human (61 , 62) P tumors (63)
-chemical inhibition of GST-P inhibits proliferation of Jurkat T cells
N-Myc -74% -c-myc family member (64)
-associated with early-onset retinoblastoma
TRADD -51 % -TNFR-associated death domain protein (65)
-involved in TNFR-induced cell growth and differentiation
NIP-1 -40% -originally described as a yeast nuclear transport protein (66)
-part of the translation initiation factor 3 (elF3) core complex (67)
DNA-Binding Transcription Factors ld-2 -65% -a member of the Id helix-loop-helix family of transcriptional inhibitors (68)
-involved in proliferation of human pancreatic cancer cells
ATF4 -42% -a member of the ATF/CREB family of transcription factors (69)
-regulates Ras-induced transformation of NIH3T3 cells
ETR103 -65% -a macrophage-associated immediate early gene (70)
ETR101 -60% -a lymphocyte-associated immediate early gene (71 )
Name % Change Function References
Cell Surface Antiαens and Adhesion Molecules
CD19 B-lymphocyte -62% -B-lymphocyte integral membrane protein (72)
Antigen -expression is down-regulated during retinoid-inhibition of lymphoblastoid B-cell proliferation
L1CAM -72% -neural cell adhesion molecule (73)
-increased L1 CAM expression is associated with high-grade migration of glioma cells β-catenin -58% -involved in cadherin-mediated cell-cell interactions (74)
-interacts with the TCF/LEF transcription factors in the Wnt signaling pathway
Integrin Subunits αM -41% -mediates cellular adherence of human neutrophils with LFA-1 β (75) -a subunit of the elastase receptor β5 -55% -β subunit of the vitronectin receptor (VR) (76) -involved in cessation of oligodendrocyte proliferation (77) -involved in murine retinal angiogenesis (78) α4 -49% -cross-linking α4 integrins inhibits LB lymphoma cell proliferation (79) -also involved in metastasis of melanoma and lymphoma cells (80) α3 -77% -a functionally perturbing α3 integrin antibody inhibits human epithelial (81) cell proliferation α6 -53% -overexpression of α6 integrin collaborates with ErbB2 to induce a (82) more malignant phenotype in NIH3T3 cells
Extracellular Signaling/Communication Proteins
Macrophage Colony- -31% -regulates the proliferation, differentiation, and survival of monocytes, (83) stimulating Factor-1 macrophages and their precursors (84)
(CSF-1) -initiates a mitogenic signal that is required throughout G1 phase -CSF-1 stably transfected ovarian granulosa cells exhibit enhanced cell proliferation
Heparin-binding EGF-like -62% -overexpressed in numerous human glioma cell lines and in a majority (85)
Growth Factor (HB-EGF) of glioblastomas
-stimulates human glioma cell proliferation
Hepatocyte Growth -81% -a transmembrane protein tyrosine kinase found to be overexpressed (86)
Factor-like Protein in hepatoblastoma and in human primary liver carcinoma (87)
(HGFLP) -induces proliferation and migration of murine keratinocytes lnhibin α -69% -a member of the inhibin family of heterodimeric growth factors (88) -inhibin α is a marker of trophoblastic neoplasia and is highly (89) expressed in virilizing adenomas
References:
37. Amati, B., Alevizopoulos, K., and Vlach, J. Myc and the Cell Cycle. Frontiers in Bioscience, 3: 250-268, 1998.
38. Huang, W. and Erikson, R.L. Signal Transduction. p. 161. Chapman and Hall, 1996.
39. Hu, W., Bellone, C.J., and Baldassare, J.J. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity. J. Biol. Chem., 274: 3396-3401, 1999.
40. Aepfelbacher, M., Essler, M., Luber, D.Q., and Weber, P.C. ADP-ribosylation of the GTP-binding protein RhoA blocks cytoplasmic division in human myelomonocytic cells. Biochem. J., 308: 853-858, 1995.
41. Jeanteur, P. The role of APC in colon cancer: Zeroing in on Myc. Bulletin du Cancer (France), 85: 925-928, 1998.
42. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor- suppressor protein. Proc. Natl. Acad. Sci. U.S.A., 92: 3046-3050, 1995.
43. Klemsz, M., Hromas, R., Raskind, W., Bruno, E., and Hoffman, R. PE-1 , a novel ETS oncogene family member, localizes to chromosome 1q21-q23. Genomics,
20: 291-294, 1994.
44. Gomez-Marquez, J., Segade, F., Dosil, M., Pichel, J.G., Bustelo, X.R., and Freire, M. The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J. Biol. Chem., 264: 8451-8454, 1989.
45. Bories, D., Raynal, M.C., Solomon, D.H., Darzynkiewicz, Z., and Cayre, Y.E. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell, 59: 959-968, 1989.
46. Kao, C.T., Lin, M., O'Shea-Greenfield, A., Weinstein, J., and Sakamoto, K.M. Over-expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells. Oncogene, 13: 1221-1229, 1996.
47. Landberg, G. and Roos, G. The Cell Cycle in Breast Cancer. APMIS, 105: 575- 589, 1997.
48. Perlaky, L, Valdez, B.C., Busch, R.K., Larson, R.G., Jhiang, S.M., Zhang, W.W., Brattain, M., and Busch, H. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res., 52: 428-436, 1992.
49. Zhuang, S.H. and Bumstein, K.L. Antiproliferative Effect of 1alpha,25- dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-dependent Kinase 2 Activity and Persistent G1 Accumulation.
Endocrinology, 139: 1197-1207, 1998.
50. Chan, A.M., Takai, S., Yamada, K, and Miki, T. Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning. Oncogene, 12: 1259-1266, 1996. 51. Ahn, N.G. and Tόlwinski, N.S. U0126: An Inhibitor of MKK/ERK Signal Transduction in Mammalian Cells. Promega Notes, 71: 4-13, 1999.
52. Coppee, F., Gerard, A.C., Denef, J.F., Ledent, C, Vassart, G., Dumont, J.E., and Parmentier, M. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. Oncogene, 13: 1471-1482, 1996.
53. Dehmel, U., Zaborski, M., Meierhoff, G., Rosnet, O., Bimbaum, D., Ludwig, W.D., Quentmeier, H., and Drexler, H.G. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia, 10: 261-270, 1996.
54. Benito, M., Valverde, A.M., and Lorenzo, M. IGF-I: a mitogen also involved in differentiation processes in mammalian cells. lnt.J Biochem. Cell Biol., 28: 499- 510, 1996.
55. Chevalier, R.L. Effects of ureteral obstruction on renal growth. Semin. Nephrol., 15: 353-360, 1995.
56. Truong, L.D., Sheikh-Hamad, D., Chakraborty, S., and Suki, W.N. Cell Apoptosis and Proliferation in Obstructive Uropathy. Semin. Nephrol., 18: 641-651, 1998.
57. Choi-Miura, N.H. and Oda, T. Relationship between multifunctional protein "clusterin" and Alzheimer disease. Neurobiol. Aging, 17: 717-722, 1996. 58. Lotan, R. Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev., 16: 349-356, 1997.
59. Hagiwara, H., Inoue, A., Nakajo, S., Nakaya, K., Kojima, S., and Hirose, S. Inhibition of proliferation of chondrocytes by specific receptors in response to retinoids. Biochem. Biophys. Res. Commun., 222: 220-224, 1996. 60. Campos, L, Oriol, P., Sabido, O., and Guyotat, D. Simultaneous expression of P- glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk. Lymphoma., 27: 119-125, 1997.
61. Lacave, R., Coulet, F., Ricci, S., Touboul, E., Flahault, A., Rateau, J.G., Cesari, D., Lefranc, J.P., and Bernaudin, J.F. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br. J. Cancer, 77: 694-702, 1998.
62. McCaughan, F.M., Brown, A.L., and Harrison, D.J. The effect of inhibition of glutathione S-transferase P on the growth of the Jurkat human T cell line. J. Pathol., 172: 357-362, 1994. 63. Kim, C.J., Chi, J.G., Choi, H.S., Shin, H.Y., Ahn, H.S., Yoo, Y.S., and Chang, K.Y. Proliferation not Apoptosis as a Prognostic Indicator in Retinoblastoma. Virchows Arch., 434: 301-305, 1999.
64. Newton, K., Harris, A.W., Bath, M.L., Smith, K.C., and Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J., 17: 706-718, 1998.
65. Gu, Z., Moerschell, R.P., Sherman, F., and Goldfarb, D.S. NIP1, a gene required for nuclear transport in yeast. Proc. Natl. Acad. Sci. U.S.A., 89: 10355-10359, 1992.
66. Phan, L, Zhang, X., Asano, K, Anderson, J., Vomlocher. H.P., Greenberg, J.R., Qin, J., and Hinnebusch, A.G. Identification of a translation initiation factor 3
(elF3) core complex, conserved in yeast and mammals, that interacts with elF5. Mol. Cell Biol., 18: 4935-4946, 1998.
67. Kleeff, J., Ishiwata, T., Friess, H., Buchler, M.W., Israel, M.A., and Korc, M. The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res., 58: 3769-3772, 1998.
68. Mielnicki, L.M., Hughes, R.G., Chevray, P.M., and Pruitt, S.C. Mutated Atf4 suppresses c-Ha-ras oncogene transcript levels and cellular transformation in
NIH3T3 fibroblasts. Biochem. Biophys. Res.Commun., 228: 586-595, 1996.
69. Shimizu, N., Ohta, M., Fujiwara, O, Sagara, J., Mochizuki, N., Oda, T., and Utiyama, H. A gene coding for a zinc finger protein is induced during 12-O- tetradecanoylphorbol-13-acetate-stimulated HL-60 cell differentiation. J. Biochem. (Tokyo.), 111: 272-277, 1992.
70. Shimizu, N., Ohta, M., Fujiwara, O, Sagara, J., Mochizuki, N., Oda, T., and Utiyama, H. Expression of a novel immediate early gene during 12-O- tetradecanoylphorbol-13-acetate-induced macrophagic differentiation of HL-60 cells. J. Biol. Chern., 266: 12157-12161, 1991. 71. Dolcetti, R., Zancai, P., Cariati, R., and Boiocchi, M. In vitro effects of retinoids on the proliferation and differentiation features of Epstein-Barr virus-immortalized B lymphocytes. Leuk. Lymphoma, 29: 269-281, 1998.
72. Tsuzuki, T., Izumoto, S., Ohnishi, T., Hiraga, S., Arita, N., and Hayakawa, T. Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. J. Clin. Pathol., 51: 13-17, 1998.
73. Young, OS., Kitamura, M., Hardy, S., and Kitajewski, J. Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. Mol .Cell Biol., 18: 2474-2485, 1998.
74. Cai, T.Q. and Wright, S.D. Human leukocyte elastase is an endogenous ligand for the integrin CR3 (CD11b/CD18, Mac-1, alpha M beta 2) and modulates polymorphonuclear leukocyte adhesion. J. Exp. Med, 184: 1213-1223, 1996.
75. De Deyne, P.G., O'Neill, A., Resneck, W.G., Dmytrenko, G.M., Pumplin, D.W., and Bloch, R.J. The Vitronectin Receptor Associates with Clathrin-coated Membrane Domains Via the Cytoplasmic Domain of its betaδ Subunit. J. Cell Sci., 111: 2729-2740, 1998.
76. Milner, R. and Ffrench-Constant, C. A developmental analysis of oligodendroglial integrins in primary cells: changes in alpha v-associated beta subunits during differentiation. Development, 120: 3497-3506, 1994.
77. Friedlander, M., Theesfeld, C.L., Sugita, M., Fruttiger, M., Thomas, M.A., Chang, S., and Cheresh, D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. U.S.A., 93: 9764-9769, 1996.
78. Bittner, M., Gosslar, U., Luz, A., and Holzmann, B. Sequence Motifs in the Integrin alpha4 Cytoplasmic Tail Required for Regulation of In Vivo Expansion of Murine Lymphoma Cells. J. Immunol., 161: 5978-5986, 1998.
79. Holzmann, B., Gosslar, U., and Bittner, M. alpha 4 integrins and tumor metastasis. Curr.Top. Microbiol. Immunol., 231: 125-141, 1998.
80. Gonzales, M., Haan, K., Baker, S.E., Fitchmun, M., Todorov, I., Weitzman, S., and Jones, J.C. A Cell Signal Pathway Involving Laminin-5, alpha3beta1 Integrin, and Mitogen-activated Protein Kinase can Regulate Epithelial Cell Proliferation. Mol. Biol. Cell, 10: 259-270, 1999. 81. Falcioni, R., Antonini, A., Nistico, P., Di, S.S., Crescenzi, M., Natali, P.G., and Sacchi, A. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp. Cell Res., 236: 76-85, 1997.
82. Roussel, M.F. Regulation of cell cycle entry and G1 progression by CSF-1. Mol. Reprod. Dev., 46: 11-18, 1997. 83. Keshava, N., Gubba, S., and Tekmai, R.R. Overexpression of Macrophage Colony-stimulating Factor (CSF-1) and its Receptor, c-fms, in Normal Ovarian Granulosa Cells Leads to Cell Proliferation and Tumorigenesis. J. Soc. Gynecol. Investig., 6: 41-49, 1999.
84. Mishima, K., Higashiyama, S., Asai, A., Yamaoka, K., Nagashima, Y., Taniguchi, N., Kitanaka, C, Kirino, T., and Kuchino, Y. Heparin-binding Epidermal Growth
Factor-like Growth Factor Stimulates Mitogenic Signaling and is Highly Expressed in Human Malignant Gliomas. Acta Neuropathologica, 96: 322-328, 1998.
85. Zhu, M. and Paddock, G.V. Expression of the Hepatocyte Growth Factor-like Protein Gene in Human Hepatocellular Carcinoma and lnterleukin-6-induced Increased Expression in Hepatoma Cells. Biochim. Biophys. Acta, 1449: 63-72,
1999.
86. Wang, M.H., Dlugosz, A.A., Sun, Y., Suda, T., Skeel, A., and Leonard, E.J. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp. Cell Res., 226: 39-46, 1996. 87. Pelkey, T.J., Frierson, H.F., Mills, S.E., and Stoler, M.H. Detection of the alpha- subunit of Inhibin in Trophoblastic Neoplasia. Hum. Pathol., 30: 26-31, 1999.
88. Arola, J., Liu, J., Heikkila, P., Voutilainen, R., and Kahri, A. Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors. Endocrine Res., 24: 865-867, 1998. 89. Kallakury, B.S., Sheehan, C.E., Rhee, S.J., Fisher, H.G., Kaufman, R.P.J., Rifkin, M.D., and Ross, J.S. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34(cdc2). Cancer, 85: 1569-1576, 1999.
Claims
1. A method of establishing a gene regulation profile of a Gingko biloba extract or a component of the Ginkgo biloba extract, which comprises the steps of: obtaining at least one batch of untreated cells; treating a first batch of cells with an extract of Ginkgo biloba or a component of the Ginkgo biloba extract to obtain a treated batch of cells; quantifying an affect on the expression of one or more genes of the treated cells to obtain a quantity of affected genes; and comparing the quantity of affected genes with a quantity of genes of cells not treated with Ginkgo biloba or a component of the Ginkgo biloba extract to obtain the gene regulation profile of the Ginkgo biloba extract or a component of the Ginkgo biloba extract.
2. A method according to claim 1 wherein the quantifying comprises: isolating poly A+ RNA from the treated batch of cells to obtain treated poly A+ RNA; isolating poly A+ RNA from a batch of untreated cells to obtain untreated poly A+ RNA; generating labeled cDNA probes from the treated poly A+ RNA to obtain treated labeled cDNA probes; generating labeled cDNA probes from the untreated poly A+ RNA to obtain untreated labeled cDNA probes; hybridizing the treated cDNA probes to an array having one or more cDNA to obtain a treated hybridized array of cDNA; hybridizing the untreated cDNA probes to an array having one or more cDNA to obtain an untreated hybridized array of cDNA; quantifying each of the cDNA of the treated hybridized array of cDNA to obtain quantities of treated cDNA; quantifying each of the cDNA of the untreated hybridized array of cDNA to obtain quantities of untreated cDNA; and comparing the quantities of each of the treated cDNA with the quantities of untreated cDNA to obtain the gene regulation profile.
3. A method according to claim 2, wherein the cells are MDA-231 cells; the
Ginkgo biloba extract is EGB 761®; and the array is a gene chip having multiple genes.
4. A method according to claim 3 wherein the gene regulation profile of
EGB 761® comprises increased expression of c-Myc protooncogene, and decreased expression of the following genes: prothymosin-α, CDK2, p55CDC, myeloblastin p120 proliferating-cell nuclear antigen, NET1, ERK2, Adenosine A2A Receptor, Flt3 ligand,
Grb2, Clusterin, RXR-β, Glutathione S-transferase P, N-Myc, TRADD, SGP-2, NIP-1, ld-2, ATF-4, ETR101, ETR-103, macrophage colony-stimulating factor-1 , heparin- binding EGF-like growth factor, hepatocyte growth factor-like protein, inhibin α, CD19
B-lymphocyte antigen, L1CAM, β-catenin, integrin subunit α3, integrin subunit α4, integrin subunit α6, integrin subunit β5, integrin subunit αM, APC, PE-1 , RhoA, c-Jun, prothymosin-α, CDK2, p55CDC and myeloblastin. 5. A method according to claim 4 wherein the gene regulation profile of
EGB 761® is about c-Myc = +75%, c-Jun = -78%,
RhoA = -93%, APC = -59%,
PE-1 = -42%,
Prothymosin-α = -79%,
Myeloblastin = -66%, p55CDC = -63%, p120 Proliferating-cell Nuclear Antigen = -68%,
CDK2 = -83%,
NET1 = -55%,
ERK2 = -46%,
Adenosine A2A Receptor = -40%, Flt3 ligand = -58%,
Grb2 = -70%,
Clusterin = -54%,
RXR-β = -55%, Glutathione S-transferase P = -39%,
N-Myc = -74%,
TRADD = -51%,
NIP-1 = -40%, ld-2 = -65%,
ATF4 = -42%,
ETR103 = -65%,
ETR101 = -60%,
CD19 B-lymphocyte Antigen = -62%, L1CAM = -72%, β-catenin = -58%,
Integrin Subunit αM = -41%,
Integrin Subunit β5 = -55%,
Integrin Subunit α4 = -49%, Integrin Subunit α3 = -77%,
Integrin Subunit α6 = -53%,
Macrophage Colony-stimulating Factor-1 (CSF-1) = -31%,
Heparin-binding EGF-like Growth Factor (HB-EGF) = -62%,
Hepatocyte Growth Factor-like Protein (HGFLP) = -81%, and Inhibin α = -69%, wherein the percentages shown can be ±20%.
5. A method according to claim 2, wherein the cells are MDA-231 cells; the component of the Ginkgo biloba extract is Ginkgolide B; and the array is a gene chip having multiple genes.
6. A method of verifying the identity of a Ginkgo biloba extract which comprises the steps of: obtaining a gene regulation profile of the Gingko biloba extract to obtain a gene regulation profile; obtaining a gene regulation profile of EGB 761® to yield an EGB 761® gene regulation profile; comparing the gene regulation profile of the Gingko biloba extract with the EGB
761® gene regulation profile; determining whether the values of the gene regulation profile of the Ginkgo biloba extract is within ±10% of the values of the EGB 761® gene regulation profile to obtain verification of the identity of the Ginkgo biloba extract.
7. A method according to claim 6, wherein the method of obtaining a gene regulation profile of the Ginkgo biloba extract and the EGB 761® gene regulation profile comprises the steps of: isolating poly A+ RNA from the treated batch of cells to obtain treated poly A+ RNA; isolating poly A+ RNA from a batch of untreated cells to obtain untreated poly A+ RNA; generating labeled cDNA probes from the treated poly A+ RNA to obtain treated labeled cDNA probes; generating labeled cDNA probes from the untreated poly A+ RNA to obtain untreated labeled cDNA probes; hybridizing the treated cDNA probes to an array having one or more cDNA to obtain a treated hybridized array of cDNA; hybridizing the untreated cDNA probes to an array having one or more cDNA to obtain an untreated hybridized array of cDNA; quantifying each of the cDNA of the treated hybridized array of cDNA to obtain quantities of treated cDNA; quantifying each of the cDNA of the untreated hybridized array of cDNA to obtain quantities of untreated cDNA; and comparing the quantities of each of the treated cDNA with the quantities of untreated cDNA to obtain the gene regulation profile.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19388900P | 2000-03-31 | 2000-03-31 | |
| US193889P | 2000-03-31 | ||
| PCT/US2001/009832 WO2001075181A2 (en) | 2000-03-31 | 2001-03-27 | Method of identifying ginko biloba in a plant extract by gene profiling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1292706A2 true EP1292706A2 (en) | 2003-03-19 |
Family
ID=22715430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01920817A Withdrawn EP1292706A2 (en) | 2000-03-31 | 2001-03-27 | Method of identifying ginko biloba in a plant extract by gene profiling |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1292706A2 (en) |
| JP (1) | JP2003529377A (en) |
| KR (1) | KR100479151B1 (en) |
| CN (1) | CN1185354C (en) |
| AU (2) | AU2001247832B2 (en) |
| CA (1) | CA2403303A1 (en) |
| CZ (1) | CZ20023275A3 (en) |
| HK (1) | HK1053150A1 (en) |
| HU (1) | HUP0301997A3 (en) |
| IL (1) | IL151856A0 (en) |
| MX (1) | MXPA02009412A (en) |
| NO (1) | NO20024611L (en) |
| NZ (1) | NZ521728A (en) |
| PL (1) | PL365418A1 (en) |
| RU (1) | RU2271393C2 (en) |
| WO (1) | WO2001075181A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020018989A1 (en) * | 1996-11-07 | 2002-02-14 | Albert Beaufour | Method of identifying pharmaceuticals from plant extracts |
| CN102869776B (en) * | 2009-12-23 | 2017-06-23 | 库尔纳公司 | HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF) |
| CN109694903A (en) * | 2019-01-09 | 2019-04-30 | 中国药科大学 | The method for synthesizing key gene with gene expression association analysis screening ginkgolides based on ginkgolides content |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037817A1 (en) * | 1998-01-26 | 1999-07-29 | Schering Aktiengesellschaft | Gene expression methods for screening compounds |
-
2001
- 2001-03-27 HK HK03105143.2A patent/HK1053150A1/en unknown
- 2001-03-27 HU HU0301997A patent/HUP0301997A3/en unknown
- 2001-03-27 NZ NZ521728A patent/NZ521728A/en unknown
- 2001-03-27 PL PL01365418A patent/PL365418A1/en not_active Application Discontinuation
- 2001-03-27 WO PCT/US2001/009832 patent/WO2001075181A2/en not_active Ceased
- 2001-03-27 RU RU2002129104/13A patent/RU2271393C2/en not_active IP Right Cessation
- 2001-03-27 JP JP2001573053A patent/JP2003529377A/en active Pending
- 2001-03-27 CA CA002403303A patent/CA2403303A1/en not_active Abandoned
- 2001-03-27 CN CNB018074847A patent/CN1185354C/en not_active Expired - Fee Related
- 2001-03-27 KR KR10-2002-7012597A patent/KR100479151B1/en not_active Expired - Fee Related
- 2001-03-27 IL IL15185601A patent/IL151856A0/en unknown
- 2001-03-27 EP EP01920817A patent/EP1292706A2/en not_active Withdrawn
- 2001-03-27 AU AU2001247832A patent/AU2001247832B2/en not_active Ceased
- 2001-03-27 CZ CZ20023275A patent/CZ20023275A3/en unknown
- 2001-03-27 MX MXPA02009412A patent/MXPA02009412A/en unknown
- 2001-03-27 AU AU4783201A patent/AU4783201A/en active Pending
-
2002
- 2002-09-26 NO NO20024611A patent/NO20024611L/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0175181A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1185354C (en) | 2005-01-19 |
| CZ20023275A3 (en) | 2003-03-12 |
| HK1053150A1 (en) | 2003-10-10 |
| MXPA02009412A (en) | 2005-02-03 |
| WO2001075181A3 (en) | 2002-11-07 |
| NO20024611D0 (en) | 2002-09-26 |
| NO20024611L (en) | 2002-11-19 |
| AU2001247832B2 (en) | 2005-07-21 |
| KR20020089409A (en) | 2002-11-29 |
| PL365418A1 (en) | 2005-01-10 |
| NZ521728A (en) | 2004-10-29 |
| CA2403303A1 (en) | 2001-10-11 |
| HUP0301997A3 (en) | 2005-11-28 |
| AU4783201A (en) | 2001-10-15 |
| IL151856A0 (en) | 2003-04-10 |
| HUP0301997A2 (en) | 2003-09-29 |
| KR100479151B1 (en) | 2005-03-28 |
| RU2271393C2 (en) | 2006-03-10 |
| WO2001075181A2 (en) | 2001-10-11 |
| CN1439059A (en) | 2003-08-27 |
| JP2003529377A (en) | 2003-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Magrangeas et al. | Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease | |
| Yang et al. | Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes | |
| Hug et al. | Measurement of the number of molecules of a single mRNA species in a complex mRNA preparation | |
| US6489159B1 (en) | Polymeric arrays and methods for their use in binding assays | |
| EP1064404B1 (en) | P53-regulated genes | |
| DE10296990B4 (en) | Using a biochip to diagnose sepsis and sepsis-like syndrome | |
| Lennon | High-throughput gene expression analysis for drug discovery | |
| US20070020623A1 (en) | Method for determining homeostasis of the skin | |
| Rafalski et al. | New experimental and computational approaches to the analysis of gene expression. | |
| AU2001247832B2 (en) | Method of profiling a plant extract | |
| AU2001247832A1 (en) | Method of profiling a plant extract | |
| EP1200108B1 (en) | Use of ginkgo extract for treating cancer which is characterized by an over-expression of peripheral-type benzodiazepine receptor protein | |
| US20060182821A1 (en) | Use of a plant extract | |
| US20030211456A1 (en) | Method of profiling a plant extract | |
| Raffelsberger et al. | Quality indicators increase the reliability of microarray data | |
| AU2005203029A1 (en) | Method of profiling a plant extract | |
| EP1691199B1 (en) | Method of predicting spot formation on the skin with the use of spot site-accelerating genes as indication and method of screening inhibitor for spot formation on the skin | |
| Chan et al. | Differential gene expression in a DNA double-strand-break repair mutant XRS-5 defective in Ku80: analysis by cDNA microarray | |
| Gebicke‐Haerter | Expression profiling methods used in drug abuse research | |
| EP1865319A1 (en) | Method of testing whether a tumor is susceptible to treatment with a ginkgo biloba extract or Ginkgolide B by testing whether the cancer is characterized by an over-expression of peripheral-type benzodiazepine receptor protein | |
| Doyu et al. | Gene expression profile in Alzheimer’s brain screened by molecular indexing | |
| Leslie et al. | Differential display: a practical approach | |
| Ruggeri et al. | 17 Amplification Strategies and DNA Biochips | |
| Au | Gene expression profiles in neonatal heart development and functional roles of calcyclin binding protein/Siah-interacting protein in terminal differentiation of cardiomyocytes | |
| HK1038595B (en) | P53-regulated genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020918 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GEORGETOWN UNIVERSITY Owner name: SOCIETE DE CONSEILS DE RECHERCHESET D'APPLICATIONS |
|
| 17Q | First examination report despatched |
Effective date: 20031215 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20060305 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1053150 Country of ref document: HK |